Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.01
+0.25 (5.25%)
Jun 29, 2026, 2:11 PM EDT - Market open
Immuneering Employees
Immuneering had 55 employees as of March 31, 2026. The number of employees increased by 2 or 3.77% since the number was last reported on December 31, 2025.
Employees
55
Change
2
Growth
3.77%
Revenue / Employee
n/a
Profits / Employee
-$989,812
Market Cap
324.13M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Abeona Therapeutics | 226 |
| Neumora Therapeutics | 92 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| Surrozen | 44 |
| Inhibikase Therapeutics | 35 |
| Eledon Pharmaceuticals | 33 |
IMRX News
- 14 days ago - Immuneering appoints Andrew Gengos as CFO - TheFly
- 14 days ago - Immuneering Appoints Andrew Gengos as Chief Financial Officer - GlobeNewsWire
- 18 days ago - Immuneering Transcript: AGM 2026 - Transcripts
- 18 days ago - Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - Immuneering announces updated clinical data from atebimetinib combination trial - TheFly
- 4 weeks ago - Immuneering Transcript: Study result - Transcripts
- 4 weeks ago - Immuneering Press release: Study result - Filings
- 4 weeks ago - Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO - GlobeNewsWire